R emote monitoring of implantable cardioverter defibrillators (ICDs) and pacemakers was first introduced in 2001. Initially, this approach added some efficiencies to device follow-up programs as well as patient convenience particularly for those who are geographically isolated from their device follow-up clinic. As the technology evolved during the past decade permitting automatic remote device interrogation as well as the availability of programmable alerts and communication of this information to healthcare providers without the active participation of the patient, this has led to improved patient benefits including early detection of device malfunction or programming concerns as well as early detection of some disease-specific parameters, such as arrhythmias and heart failure. The clinical benefits of remote monitoring have been demonstrated in many randomized clinical trials and its routine use has been recommended by professional societies. 1
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Data harbored within the device manufacturers' remote monitoring databases following hundreds of thousands of patients has provided a fertile field for patient outcomes studies. The ALTITUDE investigators used data from the Boston Scientific remote monitoring system LATITUDE to study survival in patients receiving ICDs or cardiac resynchronization therapy defibrillators. 2 In this analysis, 1-and 5-year survival rates were higher in the 69 556 patients followed remotely than in the 116 222 patients followed through device clinics only (50% relative risk reduction, P<0.001). More recently, investigators used data from 269 471 patients obtained from the St Jude Medical Merlin remote monitoring network to determine whether remote monitoring was associated with improved survival and whether this outcome was influenced by the type of device or frequency of use. 3 The authors reported that remote monitoring was associated with improved survival compared with those who never used remote monitoring, that the survival benefit was significantly improved by a high degree of compliance to this follow-up strategy and that the survival benefit was observed for patients with ICDs, cardiac resynchronization therapy systems, and pacemakers. These 2 studies have several limitations that potentially confound the data interpretations and conclusions. Patients were not randomized to the follow-up strategy and thus significant differences in the characteristics of patients followed remotely compared with those followed directly in the follow-up clinic likely exist. Apart from age and sex, no information is provided about the characteristics of patients who did not use remote monitoring or used it less frequently. No data on patient comorbidities and the severity of these comorbidities or other factors that might influence survival and other health outcomes are provided because such data are not collected in these large device monitoring databases. The Merlin registry investigators attempted to evaluate some socioeconomic factors, which are already known to be associated with health outcomes and survival by linking patient postal codes to US Census Bureau survey data. 3 Not surprisingly, factors associated with higher socioeconomic status were associated with the use of remote monitoring although the magnitude of this association was small. It is possible that users of remote monitoring are healthier, have healthcare insurance, are more engaged with their healthcare and compliant to medical therapy including follow-up and that the use of remote monitoring did not facilitate survival but is just a marker of these other traits. Indeed, analysis of a subset of the ALTITUDE cohort linked to the National Cardiovascular Data Registry ICD Registry supports this likelihood. 4 In this latter analysis involving 39 158 patients with newly implanted devices capable of remote monitoring, age, race/ethnicity, health insurance, geographic location, and health-related factors influenced the use of remote monitoring. Patients lacking health insurance, blacks, hispanics, other ethnic minorities, and those with significant comorbidities including heart failure, lung disease, and renal dysfunction were less likely to use remote monitoring.
In this current issue of Circulation: Arrhythmia and Electrophysiology, Akar et al 5 evaluated the relationship between the use of remote monitoring of ICD recipients and clinical outcomes, including all-cause mortality and all-cause rehospitalization. The data set included 37 742 patients followed in both the National Cardiovascular Data Registry ICD registry and the ALTITUDE registry. The authors report a significant reduction in mortality in patients followed with remote monitoring compared with those not using remote monitoring (hazard ratio, 0.67; 95% confidence interval [CI], 0.64-0.71; P<0.0001). Furthermore, the 3-year all-cause rehospitalization rate in the subset of Medicare patients (n=15 254) was significantly lower in the group followed with remote monitoring than in those not using this technology (hazard ratio, 0.82; 95% CI, 0.80-0.84; P<0.0001). The investigators used a multivariable time-dependent Cox model to adjust for significant patient characteristics that might have influenced the use of remote monitoring technology including age, sex, race, health insurance status, medical comorbidities, other clinical factors, and geographic factors. After adjustment for these potential confounders, the survival benefit and lower risk of rehospitalization persisted. The real strength of this study lies in linking the manufacturer's device registry data to the full set of baseline clinical data available from the NCRD registry thus permitting correction for known confounders and the authors should be congratulated on this approach.
Nevertheless, significant limitations to this analysis persist. These 3 observational studies report an association with use of remote monitoring and survival but do not demonstrate causality. Although Akar et al 5 attempt to address the issue of dissimilarities between the clinical characteristics of those engaged with remote monitoring and those not using this technology through their multivariable analysis, it is still possible that selection bias, incomplete assessment of confounding variables, or the failure to identify and measure other confounding variables contributing to the health user effect may have influenced the results. Indeed, a survival benefit of remote monitoring has not been observed in a meta-analysis of the randomized controlled trials reported to date. 6 Analysis of the pooled data reported that all-cause mortality (odds ratio, 0.83; 95% CI, 0.58-1.17; P=0.285), cardiovascular mortality (odds ratio, 0.66; 95% CI, 0.41-1.09; P=0.103), and hospitalizations (odds ratio, 0.83; 95% CI, 0.63-1.10; P=0.196) were comparable in the patients randomized to remote monitoring and those randomized to direct in clinical follow-up. The influence of home monitoring on mortality and morbidity in heart failure patients with Impaired Left Ventricular Function (IN-TIME) trial was the only randomized study to report a significant reduction in mortality with the use of remote monitoring (hazard ratio, 0.36; 95% CI, 0.17-0.74; P=0.004). 7 However, this trial was unique in the use of a central monitoring unit whose role was to ensure that remote monitoring data were reviewed and acted on by healthcare providers.
Remote monitoring may improve health outcomes through early detection of device-related issues or clinical factors that lead to early intervention to prevent appropriate or inappropriate shocks, improve delivery of cardiac resynchronization therapy therapy for heart failure or through early detection of atrial fibrillation resulting in initiation of treatment to prevent stroke and other cardiovascular consequences of this arrhythmia. If remote monitoring directly affects survival in the cardiac device population, then one would hypothesize that cardiovascular survival should be improved but such an analysis is not possible using the Social Security Death Master file as the source of vital status. Furthermore, if remote monitoring affects hospitalizations, one would predict that the reduction in hospitalizations is because of a reduction in cardiovascular/ cerebrovascular events but we are not provided with this data.
The use of the time-varying Cox regression model prevented analysis of cause-specific hospitalization (J. Akar, personal communication). This is an important issue that needs to be addressed in future data analyses.
The true impact of remote monitoring of ICDs and pacemakers on survival and rehospitalization is likely lower than reported in these observational studies. Nevertheless, the benefits of remote monitoring of implantable cardiac devices are well recognized and it is thus surprising that this technology remains underused even in geographies where its use is covered by healthcare insurance. Taken together, the results of these observational studies are intriguing and provide a compelling argument for promoting efforts to identify and eliminate the barriers currently preventing broader implementation of remote patient management strategies.
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